clinical trial · NCT04722146
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Janssen Research & Development, LLC·phase1·active not recruiting·n = 140
Multiple MyelomaTeclistamabDaratumumabPomalidomideLenalidomideBortezomibNirogacestat
brief summary
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
started
Mar 12, 2021
primary completion
Oct 3, 2025
completion
Oct 13, 2027
last updated
Jul 6, 2026
official title
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol